November 21st 2025
A combined assessment of genetic, serologic, and clinical factors may enhance early recognition of patients with RA who are most at risk for ILD.
Researchers Review Practice Guidelines for Biologics in Psoriasis
April 24th 2021Guidelines on the use of biologic drugs in patients with psoriasis were mostly seen as having medium-to-high quality; however, investigators said that more work needs to be done to ensure applicability to clinical practice.
Read More
Adalimumab, Rituximab Most Commonly Used Anti-inflammatory Agents, Says Longitudinal Study
April 23rd 2021Adalimumab was the most commonly used tumor necrosis factor-alpha inhibitor (TNFi), accounting for 47% of 90,000 incidences of TNFi use. Rituximab was the most commonly used non-TNFi, for 44% of 70,000 incidences of non-TNFi use.
Read More
Understanding the Risk of MGUS Progression to MM in Patients with Rheumatologic Diseases
April 10th 2021The risk for patients with monoclonal gammopathy of undetermined significance developing multiple myeloma is double if they have a specific category of rheumatic diseases compared with those without the diseases.
Read More
Care Disparities Persist Among White, Minority Patients With Rheumatoid Arthritis
March 4th 2021A recent study found that patients living in an an area with low socioeconomic status were less likely to be prescribed biological disease-modifying antirheumatic drugs if they were considered low-income and were male and African American.
Read More
Permanent Disability Claims for RA May Rise in Years Following COVID-19 Crisis
February 27th 2021From 1999 to 2015, permanent disability claims for patients with rheumatoid arthritis (RA) spiked during periods of economic recessions, suggesting that the COVID-19 pandemic may create a similar effect in the near future.
Read More
Among Various Biologics, Abatacept Stands Out vs Conventional Treatment for RA
February 11th 2021Abatacept was shown to have a 9% increase in likelihood of achieving remission compared with conventional therapy for rheumatoid arthritis (RA), which the researchers contribute to the treatment’s lower discontinuation rates.
Read More
Study Identifies Potential New Biomarkers of ILD in Rheumatoid Arthritis
January 6th 2021Study findings, published in Frontiers in Medicine, underscore the importance of metabolic profiling for discovering candidate screening biomarkers for interstitial lung disease (ILD) in rheumatoid arthritis.
Read More